MedTrace Logo

A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease

NCT01499225 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2014-07-31

No results posted yet for this study

Summary

This study is designed to evaluate the efficacy and the safety of YH14642 in Korea patients with chronic periodontitis, in order to investigate the recommended therapeutic dose.

Conditions

  • Chronic Periodontitis

Interventions

DRUG

YH14642 500mg Tab

YH14642 500mg per day(once a day)

DRUG

YH14642 500mg Tab

YH14642 1000mg per day(twice a day)

DRUG

YH14642 500mg Tab

YH14642 2000mg per day(three times a day)

DRUG

INSADOL[Zea mays L. extract] 35mg Tab

\[Initiation dose : 4weeks after administraion\] INSADOL\[Zea mays L. extract\] 210mg TAB per day \[Maintain dose : Between 4weeks and 8weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day \[Maintain dose : Between 8weeks and 12weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day

DRUG

DENTISTA[Doxycycline hyclate] 20mg Cap

DENTISTA\[Doxycycline hyclate\] Cap 40mg per day

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01499225 on ClinicalTrials.gov